Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma-Reference-Cited by-同舟云学术

Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma

Published:2020-01 Issue:1 Volume:12 Page:37-51
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Ambavane Apoorva¹,Yang Shuo²,Atkins Michael B³,Rao Sumati²,Shah Anshul⁴,Regan Meredith M⁵,McDermott David F⁶,Michaelson M Dror⁷

Affiliation:

1. Evidence Synthesis, Modeling, & Communications, Evidera, Inc., Bethesda, MD 20814, USA

2. Health Economics Outcomes Research, Bristol-Myers Squibb, Princeton, NJ 08540, USA

3. Department of Internal Medicine – Medical Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC 20007-2113, USA

4. Evidence Synthesis, Modeling, & Communications, Evidera, Inc., Waltham, MA 20814, USA

5. Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA

6. Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA 02215, USA

7. Massachusetts General Hospital Cancer Center, Boston, MA 02214, USA

Abstract

Aim: To assess the cost–effectiveness of treatment sequences for patients with intermediate- to poor-risk advanced renal cell carcinoma. Patients & methods: A discrete event simulation model was developed to estimate patients’ lifetime costs and survival. Efficacy inputs were derived from the CheckMate 214 and CheckMate 025 studies and network meta-analyses. Safety and cost data were obtained from the published literature. Results: The estimated average quality-adjusted life-years (QALYs) gained was the highest on nivolumab + ipilimumab-initiated sequences (3.6–5.3 QALYs) versus tyrosine kinase inhibitor (TKI)-initiated sequences (2.1–3.7 QALYs). Incremental cost per QALY gained for nivolumab + ipilimumab-initiated sequences was below the willingness-to-pay threshold of $150,000 versus other sequences. Conclusion: Immuno-oncology combination therapy followed by TKIs is cost-effective versus TKI sequences followed by immuno-oncology or sequencing TKIs.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2019-0199

Reference42 articles.

1. American Cancer Society. Cancer facts & figures (2017). www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html

2. Current management options in metastatic renal cell cancer

3. Howlader N, Noone AM, Krapcho M SEER cancer statistics review (CSR), 1975–2016, National Cancer Institute. https://seer.cancer.gov/csr/1975_2016

4. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

5. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?;European Urology Open Science;2023-09

3. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma;European Urology Oncology;2023-06

4. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment;Nature Reviews Urology;2023-03-16

5. Discrete-Event Simulation in Healthcare Settings: A Review;Modelling;2022-10-14